Advances in Radio-Frequency Transdermal Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advances in Radio-Frequency Transdermal Drug Delivery
A microelectronic system based on radio-frequency (RF) cell ablation addresses limitations of other transdermal drug-delivery methods. This system expands the transdermal spectrum to include the delivery of water-soluble molecules, peptides, proteins, and other macromolecules.


Pharmaceutical Technology



AUTHOR
Passive transdermal drug delivery has been used for more than 20 years, but faces certain limitations with the type of active molecules that may delivered through this route. Very few drugs can passively diffuse across the skin barrier at therapeutically useful rates. Cell ablation using a radio-frequency (RF) alternating electrical current is a well known, proven medical technology that can be applied to drug delivery to overcome this obstacle. RF ablation is a safe, low-cost technique and a familiar concept in medical practice. When properly modified, RF cell-ablation technology may also create microchannels in the skin's surface to enable transdermal delivery of drugs.

Radio-frequency cell-ablation technology


Figure 1
RF ablation is a well-known medical technology to eliminate living cells. It is widely used to cut through tissues in minimally invasive operations or to destroy small tumors in the kidney and liver (1–5). RF ablation is performed by placing a conducting wire on a body area and passing an alternating electrical current at a frequency above 100 KHz (radio frequency) through the area. The ions in the cells adjacent to the electrodes vibrate as they try to follow the change in electrical current direction. These vibrations cause heat, which results in water evaporation and cell ablation. RF microchannels are created by placing a closely spaced array of tiny electrodes with very precise dimensions against the skin (see Figure 1). The alternating electrical current is transferred through each of the microelectrodes, ablates the cells underneath each electrode, and forms microscopic passages in the stratum corneum and outer dermis (6, 7). These RF microchannels penetrate only the outer layers of the skin, where there are no blood vessels or nerve endings. This action minimizes skin trauma and unpleasant sensations. The process is performed in seconds. Immediately after formation, the microchannels fill with interstitial fluid, which is responsible for the hydrophilic nature of the microchannels. As a result, microchannels serve as aquatic channels into the inner layers of the skin. They are embedded in the surrounding of the hydrophobic stratum corneum. For drug delivery, the microchannels may last up to 24 h. At 36 h, the delivery through treated skin returns to the values of intact skin.

A major difficulty in penetrating the skin for drug delivery is that the texture and softness of the skin change from site to site and from person to person. To address these variations, a unique microelectrode-array design was used. This microelectrode array design adapts to these differences in skin type within and between treatment sites. This design is essential to forming RF microchannels with consistent, well-controlled depths, enabling the drug to reach the capillary bed without unnecessary trauma to the inner layers of the skin (8).

Drug delivery device


Figure 2
The "ViaDerm" (TransPharma Medical Ltd., Lod, Israel) system is an example of a microelectronic system based on RF cell ablation for transdermal drug delivery. The system consists of the device, which is used to pretreat the skin and form the RF microchannels in the outer layers of the skin, and a patch containing the drug, which is placed on top of the pretreated skin (see Figure 2).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here